Gardani Carla Fernanda Furtado, Diz Fernando Mendonça, Dondé Luísa Brandalise, Rockenbach Liliana, Laufer Stefan, Morrone Fernanda Bueno
Escola de Medicina, Programa de Pós-Graduação em Medicina e Ciências da Saúde, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
Laboratório de Farmacologia Aplicada, Escola de Ciências da Saúde e da Vida, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
Front Immunol. 2024 Sep 17;15:1455469. doi: 10.3389/fimmu.2024.1455469. eCollection 2024.
Purines and pyrimidines are signaling molecules in the tumor microenvironment that affect cancer immunity. The purinergic signaling pathways have been shown to play an important role in the development and progression of cancer. CD39 and CD73 are ectonucleotidases responsible for breaking down ATP or ADP into adenosine, which regulates immunosuppression in various types of cancer. These enzymes have been studied as a potential therapeutic target in immunotherapy, and recent research suggests a correlation between ectonucleotidases and clinical outcomes in cancer.Prostate cancer is the most diagnosed cancer in men, after non-melanoma skin tumors, and is the second leading cause of death in men in the world. Despite having long survival periods, patients often receive excessive or insufficient treatment. Within this complex landscape, the adenosine/CD73 pathway plays a crucial role. Therefore, this review aims to highlight new findings on the potential role of purinergic signaling in cancer treatment and emphasizes the importance of anti-CD73 as a pharmacological strategy for prostate cancer therapy.
嘌呤和嘧啶是肿瘤微环境中影响癌症免疫的信号分子。嘌呤能信号通路已被证明在癌症的发生和发展中起重要作用。CD39和CD73是外核苷酸酶，负责将ATP或ADP分解为腺苷，从而调节各种类型癌症中的免疫抑制。这些酶已被作为免疫治疗的潜在靶点进行研究，最近的研究表明外核苷酸酶与癌症的临床结果之间存在关联。前列腺癌是男性中仅次于非黑色素瘤皮肤肿瘤的最常被诊断出的癌症，也是全球男性第二大死因。尽管生存期较长，但患者常常接受过度或不足的治疗。在这一复杂的情况下，腺苷/CD73通路起着关键作用。因此，本综述旨在突出嘌呤能信号在癌症治疗中潜在作用的新发现，并强调抗CD73作为前列腺癌治疗药理学策略的重要性。
